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ABSTRACT
Mutations in human mitochondrial DNA are often
associated with incurable human neuromuscular
diseases. Among these mutations, an important
number have been identified in tRNA genes, includ-
ing 29 in the gene MT-TL1 coding for the
tRNALeu(UUR). The m.3243A>G mutation was desc-
ribed as the major cause of the MELAS syndrome
(mitochondrial encephalomyopathy with lactic
acidosis and stroke-like episodes). This mutation
was reported to reduce tRNALeu(UUR) aminoacylation
and modification of its anti-codon wobble position,
which results in a defective mitochondrial protein
synthesis and reduced activities of respiratory chain
complexes. In the present study, we have tested
whether the mitochondrial targeting of recombinant
tRNAs bearing the identity elements for human mito-
chondrial leucyl-tRNA synthetase can rescue the
phenotype caused by MELAS mutation in human
transmitochondrial cybrid cells. We demonstrate
that nuclear expression and mitochondrial targeting
of specifically designed transgenic tRNAs results in
an improvement of mitochondrial translation, incre-
ased levels of mitochondrial DNA-encoded respira-
tory complexes subunits, and significant rescue
of respiration. These findings prove the possibility
to direct tRNAs with changed aminoacylation
specificities into mitochondria, thus extending the
potential therapeutic strategy of allotopic expres-
sion to address mitochondrial disorders.
INTRODUCTION
The m.3243A>G mutation in the mitochondrial DNA
(mtDNA) MT-TL1 gene coding for mitochondrial
tRNALeu(UUR) (mt-tRNALeu(UUR)) was ﬁrst identiﬁed as
a genetic cause of mitochondrial encephalomyopathy with
lactic acidosis and stroke-like episodes (MELAS, MIM
5400 000) (1). It is one of the most common mitochondrial
pathogenic mutations with a carrier frequency estimated
in the range between 0.95 and 18.4/100 000 in northern
European populations (2–4). Like many mutations affect-
ing mitochondrial respiratory chain, the m.3243A>G
mutation is associated not only with MELAS, but also
with other clinical phenotypes, including CPEO (Chronic
Progressive External Ophthalmoplegia), DMDF
(Diabetes Mellitus and DeaFness), etc. (5). In all cases,
the m.3243A>G mutation was present in a heteroplasmic
state, which means the co-existence of mutant and
wild-type mtDNA molecules in one cell. The proportion
of mutant mtDNA molecules that leads to the manifest-
ation of the disease varied strongly in different tissues (6).
Patients with m.3243A>G mutation often show severe re-
spiratory chain deﬁciency with complexes I and IV
affected in a ﬁrst place (7,8), but the precise mechanism
connecting the mutation with clinical phenotypes is still
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not fully understood. Accumulated data, mostly obtained
on transmitochondrial cybrid cells, suggest a deﬁciency of
aminoacylation of mutant mt-tRNALeu(UUR) (9–13) and
hypomodiﬁcation of its anti-codon wobble position affect-
ing recognition of UUG codons (14–17) to be the origin of
a mitochondrial translation defect. This leads to a decrease
of respiratory chain complexes steady-state levels (7,18)
and affected respiration rate (11,19,20). The mitochon-
drial translation defect observed varied from moderate
in some cell lines to severe in others. Moreover, different
groups reported qualitatively different patterns of mito-
chondrial translation in cells bearing the m.3243A>G
mutation. In association with the mutation, it has been
observed that there was a speciﬁc decrease of polypeptides
rich in UUG codons (for instance, ND6) and appearance
of abortive translation products (18,20). In other reports,
no qualitative differences or speciﬁc correlation between
number of leucine UUR codons and level of synthesis of
particular mitochondrial proteins were found (11,21). The
data on amino acid misincorporation at UUR codons are
also somewhat controversial (18,22,23).
Up to now, no efﬁcient therapy for MELAS and other
mitochondrial diseases has been demonstrated.
Antioxidants and vitamins have been used, but there
have been no consistent successes reported (24). Spindle
transfer, where the nuclear DNA is transferred to another
healthy egg cell leaving the defective mtDNA behind, is a
potential treatment procedure that has been successfully
carried out on monkeys (25). Using a similar pronuclear
transfer technique, healthy DNA in human eggs from
women with mitochondrial disease was successfully trans-
planted into the eggs of women donors who were un-
affected (26). Embryonic mitochondrial transplant and
protofection have been proposed as a possible treatment
for inherited mitochondrial disease. Allotopic expression
of mitochondrial proteins (i.e. expression of mtDNA-
encoded mitochondrial proteins in the nucleus) was also
tested as a radical treatment for mtDNA mutation load.
Promising results were obtained with MELAS cybrid cells
overexpressing the mitochondrial leucyl-tRNA synthetase
(mt-LeuRS) (27,28). Authors observed an increase in
steady-state level of aminoacylated mt-tRNALeu(UUR),
partial restoration of COX1, COX2 and ND1 steady-state
levels and increase of respiration rate. Interestingly, the
rate of mitochondrial protein synthesis was almost the
same as that in parental cells bearing MELAS mutation.
Authors suggested that mutation suppression occurred via
a mechanism that increased protein stability rather than
translation rate. In an independent study, overexpression
of mitochondrial translation factors EFTu and EFG2 in
myoblasts derived from a MELAS patient partially
restored mitochondrial translation, steady-state levels
of certain respiratory chain subunits, assembly and
activity of the OXPHOS complexes (18). A similar
approach was also formerly and successfully modelled in
yeast (29).
In addition to proteins, human mitochondria also im-
port from the cytosol small RNAs such as 5S rRNA
(30–32,34), tRNAGln (33), or RNase P and MRP RNA
components (35,36). Moreover, we previously
demonstrated that yeast importable tRNALys derivatives
and some other small artiﬁcial RNA substrates could be
imported into mitochondria after their expression in
human cells (37,38). We have shown that yeast tRNALys
derivatives targeted to mitochondria of cybrid cells or
patient ﬁbroblasts with the m.8344A>G mutation in the
mtDNA MT-TK gene coding for mt-tRNALys
(commonly associated with the MERRF syndrome) par-
tially restored their mitochondrial translation, activity of
respiratory complexes, electrochemical potential across
the mitochondrial inner membrane and respiration rate
(39). In order to enlarge the spectrum of mtDNA muta-
tions addressed we investigated here the possibility to
rescue the MELAS mutation by allotopic expression of
recombinant and importable tRNAs whose aminoacyla-
tion identity had been changed from lysine to leucine.
MATERIALS AND METHODS
Cell culture
The MELAS cybrid cell line used in this study was kindly
provided by E. A. Shoubridge (Montreal Neurologic
Institute, Quebec, Canada). It carried 90±5% of
m.3243A>G mutation and was functionally characterized
previously (40). They were generated by fusing rho0 cells
from osteosarcoma cell line 143B.TK with cytoplasts
from clonal primary myoblasts established from a
patient carrying the m.3243A>G point mutation in
MT-TL1 gene (MELAS mutation) as described elsewhere
(41). Cybrid cells were cultivated in DMEM medium with
high glucose (4.5 g/l), sodium pyruvate (110mg/l) and
L-glutamine (2mM) from Sigma, supplemented with
10% (w:v) fetal calf serum (FCS), 50mg/ml uridine,
standard concentrations of antibiotics (penicillin, strepto-
mycin and fungizone) and, for stable transfectants, 2 mg/
ml of puromycin. 143Brho+ cells were used as healthy cell
control and were cultivated in the same conditions as
MELAS cybrid cells. HEK-293T cells were used for pro-
duction of lentiviral particles and were cultivated in
standard DMEM medium with 1 g/l glucose. All cell
lines were cultivated at 37C and 5% of CO2.
Cell transfection
Transfection of MELAS cybrid cells with tRNA tran-
scripts was performed using Lipofectamine2000
(Invitrogen) as described previously (32) with minor modi-
ﬁcations: 1 mg of transcript and 12.5ml Lipofectamine2000
were used per 2 106 cells. Transient transfection was per-
formed with a mix of 4 mg of pBK-CMV-tRK plasmid and
12 ml of Lipofectamine2000 per 600 103 cells according
to manufacturer protocol. Efﬁciency of transfection was
estimated by FACS analysis of GFP expression from
pmax-GFP plasmid transfected in parallel. MELAS
cybrid cells stably expressing recombinant tRNAs were
obtained by lentiviral transfection. Production of
lentiviral particles was performed in HEK-293T cells
using FuGENE6 transfection reagent (Roche Applied
Sciences), 3 mg of pLKO.1-tRK (Addgene), 1.5 mg of
pLP1, 0.75 mg of pLP2 and 0.75 mg pLP-VSGV packaging
plasmids (Invitrogen) according to manufacturer protocol.
Infection of MELAS cybrid cells was performed with
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virus-containing medium from HEK-293T cells during
2–3 days. Cells containing transgenes were selected in
the presence of 2mg/ml of puromycin during 2–3 days.
Construction of recombinant tRNA genes and plasmids
The hmtLeuRS gene without mitochondria-targeting
sequence (186–302 nucleotides coding for the ﬁrst 39
amino acids), was PCR-ampliﬁed from cDNA purchased
from the RIKEN collection and cloned in the expression
pET3a (Ampr) vector.
Cloning of yeast tRK1, tRK2 (G1-C72; G73; U34) and
tRK3 genes was performed previously (42). tRNA genes
coding sequences were placed under control of T7
promoter in pUC19 (Ampr) (Invitrogen), BstNI site was
introduced at its 30-terminus to further generate the
CCA-30 sequence in the T7 transcript. Mutations aimed
to change tRNA aminoacylation identity (Lys>Leu) were
introduced by several steps of PCR-mutagenesis.
Discriminator base A73—using oligonucleotides: tRK1-
T7 GGGATCCATAATACGACTCACTATA GCCTT
GTTGGCG, tRK1-A73-BstNI GGGATCCTGGTGC
CCTGTAGGGGGCTCG, tRK2-G1-T7 GGGATCCA
TAATACGACTCACTATAGCCTTGTTAGCTCAG,
tRK2-C72A73-BstNI GGGATCCTGGTGCCTCATAG
GGGGCTCG. Anti-codon substitution was performed
by Quick Change Site-Directed Mutagenesis Kit
(Stratagene) according to manufacturer protocol. The fol-
lowing pairs of oligonucleotides were used (‘As’ for
forward and ‘Br’ for reverse): tRK1UAAAs GACTTAA
AATCATAAGG, tRK1UAABr TATGATTTTAAGTC
ATACGC, tRK1CAAAs GACTCAAAATCATAAGG,
tRK1CAABr TATGATTTTGAGTCATACGC,
tRK2UAAAs GTTCGGCTTAAAACCG, tRK2UAABr
CATTTCGGTTTTAAGCCG, tRK2CAAAs GTTCGG
CTCAAAACCG, tRK2CAABr CATTTCGGTTTTG
AGCCG, tRK3UAAAs GTCTTAAAAGCAACCC,
tRK3UAABr GCTTTTAAGACAAC, tRK3CAAAs CA
GTTGTCTCAAAAGCAACCC, tRK3CAABr GGGTT
GCTTTTGAGACAACTG.
For transient expression in MELAS cybrid cells,
tRK1UAA/CAA, tRK2UAA/CAA, tRK3UAA/CAA
genes we cloned in pBK-CMV (Kanr) vector (Stratagene)
in BglII/BamHI (BglII in the fragment and cohesive site
BamHI - in the vector) sites using oligonucleotides:
TRK1/F1-Aviv GGCAAGATCTGGTCAGATTTCCA
ATAACAGAATATCCTTGTTAGCCTTGTTGGCG,
TRK1/F1-A73-Bviv GGCAAGATCTGTCATCGTGTT
TTAAAAAAAAAAAGAATGCCCTGTAGGGGGCT
C, TRK2/F1-G1-Aviv GGCAAGATCTGGTCAGATTT
CCAATAACAGAATATCCTTGTTAGCCTTGTTAG
CTCAG, TRK2/F1-C72A73-Bviv GGCAAGATCTGTC
AT CGTGTTTTAAAAAAAAAAAGAATGCCTCATA
GGGGGCTCG, TRK3/F1-Aviv CCCAAGAGATCTG
GTCAGATTTCCAATAACAGAATAGAGAATATTG
TTTAATG, TRK3/F1-Bviv CCCAAGAGATCTGTCA
TCGTGTTTTAAAAAAAAAAAGAATGAGAATAG
CTGGAGTTG. tRNA genes were ﬂanked by non-coding
ﬂanking regions of one of the well expressed tRK1 copies
and were cloned in an opposite direction with respect to
the CMV promoter in order to favour their transcription
from internal promoter by RNA polymerase III (RpoIII)
and further correct maturation.
For stable transfection tRK1UAA/CAA, tRK2UAA/
CAA genes were cloned in plKO.1 (Ampr) lentiviral
vector (Addgene) (43) in AgeI/EcoRI sites under the con-
trol of external U6-promoter without any ﬂanking regions
using oligonucleotides: trk1plkoAs GGCAACCGGTGC
CTTGTTGGCG, trk1plkoBr GGCAGAATTCAAAAA
TGCCCTGTAGGG, trk2plkoAs GGCAACCGGTGCC
TTGTTAGCTCAG, trk2plkoBr GGCAGAATTCAAA
AATGCCTCATAGGGGG.
Puriﬁcation of hmtLeuRS and in vitro aminoacylation
assay
His-tagged hmtLeuRS and hmtLysRS were puriﬁed to
homogeneity from BL21 CodonPlus (DE3)-RIL
Escherichia coli strain through nickel afﬁnity chromatog-
raphy, followed by protein concentration through Nanosep
30K (Pall) columns, and stored as 40% glycerol solution
at 20C. Activities of different enzyme fractions were
tested on commercially available preparation of E. coli
tRNA. Aminoacylation of tRNA T7-transcripts was done
according to the described procedure (44). Final conditions
were: 50 mLHEPES–NaOH (pH 7.6), 25 mLNaCl, 12 mL
MgCl2, 2.5 mL ATP, 0.2mg/ml BSA, 0.8mM [
3H]-Leu or
0.8mM [3H]-Lys (>400Ci/mmole, NEC) and adapted con-
centrations of tRNA and enzyme. Aminoacylation rates
and Km were measured as described elsewhere (45,46).
Aminoacylation efﬁciencies of recombinant tRNA tran-
scripts were compared to that of wild-type human
mt-tRNALeu(UUR) and mt-tRNALys T7-transcripts.
Isolation and analysis of DNA
Total cellular DNA was isolated by standard procedures
and the m.3243A>G mutation level was tested systemat-
ically by ApaI restriction analysis, as described elsewhere
(47). Brieﬂy, mutation containing mtDNA region was
PCR-ampliﬁed using oligonucleotide primers: hp3081 G
TAATCCAGGTCGGTTTCT and hp3380 CGTTCGGT
AAGCATTAGG, PCR-products were digested by ApaI
for 2 h and analyzed by gel-electrophoresis.
Isolation and analysis of total and mitochondrial RNAs
Total and mitochondrial RNAs were isolated by standard
TRIzol-extraction (Invitrogen) from cells and puriﬁed
mitochondria, respectively. Mitochondria were isolated
from cells as described previously, using the differential
centrifugation protocol (48). RNA preparations were
analyzed by Northern-hybridization with [32P]-50-end-
labelled oligonucleotide probes. To detect tRK1 versions
we used oligonucleotide probe anti-tRK1 (1–34): GAGTC
ATACGCGCTACCGATTGCGCCAACAAGGC, for
tRK2 versions, the probe anti-tRK2 (2–32): GCCGAACG
CTCTACCAACTCAGCTAACAAGG, for tRK3 versions,
the probe anti-tRK3 (1–39): CTTAAAAGACAACTGTT
TTACCATTAAACAAATATTCTC. The probes anti-
mt-tRNALeu: GAACCTCTGACTCTAAAG and anti-
mt-tRNAThr: CATCTCCGGTTTACAAG were used to
control the quality of mitochondrial RNA. The
probes anti-cy-tRNALys: CTTGAACCCTGGACC and
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anti-cy-5.8SrRNA: AAGTGACGCTCAGACAGGCA
to control the absence of contamination of mitochondrial
RNA by cytosolic RNA.
Analysis of aminoacylation in vivo
Analysis of aminoacylation levels of recombinant tRNAs
in vivo was performed through PAGE in acid conditions
and subsequent Northern hybridization analysis as desc-
ribed elsewhere (49). Brieﬂy, RNAs from cells were
isolated with TRIzol-reagent (Invitrogen), precipitated on
ice with 50% isopropanol and dissolved in 10mM Sodium
acetate pH4.5, 1mM EDTA. Deacylated controls were
prepared by 30min incubation at 37C in 0.25M
Tris-HCl pH8.5, 0.25M MgCl2 followed by RNA precipi-
tation. RNAs in a loading buffer with 0.1M Sodium
acetate pH5.0 were run in a cold room through 35 cm
long denaturing acid 6.5% PAAG with 0.1M Sodium
acetate pH5.0 and analyzed by Northern hybridization
with [32P]-50-end-labelled oligonucleotide probes.
Immunoblotting
For immunoblotting, whole cells were solubilized in a
Laemmli’s buffer (50) in the way to have SDS: protein
ratio 25–30 (w/w), sonicated for 5 s to break cellular
DNA; incubated for 10min at 60C, and 30 mg of protein
were run on a 12.5% SDS–PAGE, and subsequently
transferred to a nitrocellulose membrane. When several
cell lines were compared, we either used the same ﬁlter
cut at the levels of different proteins of interest or separate
runs of equal aliquots of the same protein extract with
simultaneous electrotransfer, to ensure the comparability
of the results. In all cases the amount of analyzed proteins
was in the linear area of signal detection, as veriﬁed by in-
gel titration with following scanning in the Typhoon-Trio.
In no case the signal was saturated in the experiments
presented. For immunodetection following antibodies were
used: polyclonal antibodies against COX2, ND1 and com-
mercially available monoclonal antibodies against porin
(Calbiochem 529538), a-tubulin (Sigma T6074).
Detection was done either using ECLTM horseradish per-
oxidase linked secondary antibodies and ‘ECL Plus
Western Blotting Detection Reagent’, or using ECL
PlexTM Cy3 and Cy5-conjugated secondary antibodies,
on Typhoon-Trio (all from GE Healthcare). Signal quan-
tiﬁcation was performed in ImageQuantTL programme
from the same manufacturer.
In vivo mitochondrial translation
The analysis of mitochondrial protein synthesis was per-
formed as previously described (39) with minor modiﬁca-
tions. Brieﬂy, 600 103 cells were incubated for 10min in
DMEM w/o methionine (Sigma) in the presence of
100mg/ml of emetine to inhibit cytoplasmic translation,
followed by 30min with 200 mCi/ml [35S]-methionine
(>1000Ci/mmole, GE Healthcare), and, ﬁnally, 10min
chase in the normal growth medium. Cells were solubilized
in a Laemmli’s buffer (50), sonicated for 5 s to fragmentize
chromosomal DNA; incubated for 10min at 37C, and
100mg of protein were run on a 10–20% gradient SDS–
PAGE. Protein amounts loaded were before normalized
by anti-porin immunoblotting of the same preparations.
Visualization and quantiﬁcation were performed using
Typhoon-Trio and ImageQuantTL software from GE
Healthcare.
Measurement of oxygen consumption
The rates of oxygen consumption were measured using
Hansatech Oxygraph. Respiration of intact (non-
permeabilized) cells was measured using 1–2 106 cells/ml
in PBS in the presence of 5mM glucose. A 1 mg/ml of
oligomycin, FCCP in the range of 10–500 nM and 1mM
of KCN were sequentially added to measure coupled,
uncoupled and non-mitochondrial oxygen consumption,
respectively.
The rates of substrate dependent oxygen consumption
were measured on 1–2 106 cells/ml in a respiration buffer
containing 20mM HEPES–KOH (pH 7.4), 200mM
sucrose, 3mM MgCl2, 10mM KH2PO4, 0.5mM EGTA
and 1 g/l of BSA. Cells were permeabilized by digitonin
[100 mg of digitonin per 1mg of total cell protein (1 106
cells)]. Succinate was used to donate electrons at Complex
II level, while Complex I was inhibited by 0.5mM
rotenone. Ascorbate was used to donate electrons at
Complex IV level, while both Complex I and Complex
II (by 5mM malonic acid) were inhibited. Maximal
possible respiration rates were measured in the presence
of the uncoupler FCCP (50–500 nM) and oligomycin
(1 mg/ml). Non-mitochondrial oxygen consumption was
measured at the end of each experiment upon addition
of 1mM KCN.
RESULTS
Construction of importable tRNAs with leucine
aminoacylation identity
The major identity elements required for recognition of
tRNALeu(UUR) by mitochondrial LeuRS are ‘discrimin-
ator’ base A73 and the A14 base (affected by
m.3243A>G mutation) (Figure 1) (44,45). Among yeast
tRNA derivatives mitochondrially importable in vivo in
human cells we have previously characterized three
lysine isoacceptor tRNAs (tRKs). Two of them are cyto-
solic type tRNAs: wild-type tRK1 and recombinant tRK2
(G1-C72; G73; U34). The third—a mitochondrial-type :
tRK3, which can be nuclearly expressed and then targeted
into mitochondria (Figure 1) (39). We introduced in these
three tRNAs the discriminator base A73 and leucine anti-
codons, either UAA or CAA. The ﬁrst one with the ex-
pectation that the U in the wobble position would be
correctly modiﬁed, the last one with the purpose to
decode UUG codons even if the anticodon will be not
modiﬁed. Therefore, six different versions of potentially
therapeutic tRNAs: tRK1UAA, tRK1CAA, tRK2UAA,
tRK2CAA, tRK3UAA and tRK3CAA were designed and
further used for in vitro and in vivo assays (Figure 1). All
these versions were compared for their capacity to be
aminoacylated by recombinant human mitochondrial
leucyl-tRNA- and lysyl-tRNA synthetases (Table 1). As
expected, all versions gained the capacity to be leucinylated
with efﬁcienies comparable with that of human mt-
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tRNALeu (the tRK2CAA version having a lowest efﬁ-
ciency, but still at the level of 37% in comparison with
the cognate tRNA). On the other hand, we observed that
most of the version also retained a low capacity to be
lysinylated. The best version from the point of view of
aminoacylation properties was tRK1CAA, which was as
well leucinylated as the cognate mt-tRNALeu and retained
a lowest lysinylation capacity (6% of mt-tRNALys).
We tested then whether new recombinant tRNAs
preserved their ability to be imported into mitochondria
of human cells. To this end, MELAS cybrid cells were
transfected with corresponding T7-transcripts, total and
mitochondrial RNAs from cells were isolated 24 h after
transfection and analyzed by Northern hybridization with
32P-50-end labelled oligonucleotide probes (Figure 2A).
The import capacity of different recombinant tRNAs
was evaluated as a ratio of the hybridization signal cor-
responding to the recombinant RNA in puriﬁed mito-
chondrial RNA fraction to that of human mt-tRNALeu
in the same isolate. It was then expressed as relative value
in comparison with the import of tRK1 or tRK3 tran-
scripts taken as 1.0 in each series. All synthetic tRNAs
tested were found to be imported into mitochondria of
MELAS cybrid cells in vivo with various efﬁciencies
(Figure 2B). Mutations introduced in the anti-codon re-
gion of tRK3UAA (U35:A35, U36:A36) and tRK3CAA
(U34:C34, U35:A35, U36:A36) did not signiﬁcantly reduce
efﬁciency of their import, while substitutions made in
tRK1UUA (U73:A73, C34:U34, U35:A35, U36:A36)
and tRK1CAA (U73:A73, U35:A35, U36:A36) decreased
their import 3- and 5-fold, respectively, compared to tRK1
without mutations. Import efﬁciency of tRK2CAA was
estimated comparing to tRK1 transcript, since wild-type
tRK2 is not imported into mitochondria (42,51–53), and
its import was approximately seven times lower when
compared to tRK1.
Using the same approach, we found that T7-transcripts
were stable in transfected cells at least 48 h after transfec-
tion. Despite efﬁcient targeting into mitochondria of all
synthetic recombinant tRNAs, we were not able to observe
any effect on mitochondrial translation (data not shown).
Moreover, the analysis of aminoacylation state of these
transcripts using the acid gel method (49) showed that
they were mostly present in deacylated form, a ﬁnding
which could be explained by the absence of posttranscri-
ptional modiﬁcations in T7-transcripts. To overcome this
problem, the experiments were axed at in vivo expression
of the recombinant tRNAs.
Figure 1. Cloverleaf structures of tRNAs used in this study. From left to right: native human mitochondrial tRNALeu(UUR), major identity
elements of recognition by mtLeuRS are in blue ﬁlled circles and MELAS m.3243A>G mutation is indicated by the red arrow; three yeast
lysine tRNAs, tRK1, tRK2; tRK3 and their recombinant versions, tRK1UAA/CAA, tRK2UAA/CAA, tRK3UAA/CAA, with determinants of
mitochondrial import indicated in green ﬁlled circles, identity elements for human mtLeuRS are in blue ﬁlled circles, mutations and regions where
they were introduced are indicated by arrows and enclosed in blue for leucine aminoacylation identity elements, in green—for import determinants
and in red—for leucine anticodons. Post-transcriptional modiﬁcations: 5-taurinomethyluridine (tm5U), 5-methylcarboxymethyl-2-thiouridine
(mcm5s2U), 5-carboxymethylaminomethyl-2-thiouridine (cmnm5s2U), 1-methylguanosine (m1G), 2-methylguanosine (m2G), 7-methylguanosine
(m7G), 1-methyladenosine (m1A), 5-methylcytidine (m5C), pseudouridine (), dihydrouridine (D), 5-methyluridine (T) and
N6-threonylcarbamoyladenosine (t6A).
Table 1. Aminoacylation of tRK mutant versions by recombinant
human mitochondrial LeuRS et LysRS
tRNA Km
(mM)
V (pmoles
103/min)
V/Km Relative
efﬁciency of
aminoacylation (%)
LysRS
mt-tRNALys 1 50 50.0 100
tRK3 0.3 25 83.3 167
tRK2CAA 0.9 27.5 30.6 61
tRK2UAA 2.2 50 22.7 45
tRK3CAA 3.7 21 5.7 11
tRK3UAA 8 75 9.4 19
tRK1CAA 4.2 12.5 3.0 6
tRK1UAA 1.9 31 16.4 33
LeuRS
mt-tRNALeu 0.5 62.5 125.0 100
tRK2CAA 0.8 37 46.3 37
tRK2UAA 0.6 80 133.3 107
tRK3CAA 0.65 59 90.8 73
tRK3UAA 0.6 60 100.0 80
tRK1CAA 0.7 81 115.5 93
tRK1UAA 0.55 58 105.5 84
T7-transcripts were used as substrates. The mean values presented are
the result of several (n> 3) independent measures with the error <10%.
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Analysis of transient expression of recombinant tRNAs in
MELAS cybrid cells
In order to express functional recombinant tRNAs in
cybrid cells, we performed transfection with DNA con-
structs containing corresponding mutated genes. To this
end, we ﬁrst used mammalian expression vector pBK-
CMV and cloned recombinant tRNA genes in an opposite
direction with respect to the CMV promoter in order to
favour their transcription from their internal promoter for
RNA polymerase III (RpoIII) and their further correct
maturation. MELAS cybrid cells were transiently trans-
fected with pBK-CMV-tRK plasmids with the efﬁciency
close to 90% (as revealed by FACS analysis of the trans-
fection control with a GFP-expressing plasmid). Total
cellular RNA was then analyzed by Northern hybridiza-
tion 24 h, 48 h and 72 h after transfection to check expres-
sion and stability of recombinant tRNAs. tRK1 and
tRK2-based versions were stable for 24 h, while their
amount strongly decreased at day 2 (Figure 3A).
Expression of tRK3 versions was not detected, which
can be explained by non-optimal sequence of internal
promoter for RpoIII in these transgenes as compared to
tRK1/tRK2 versions. In order to increase the period
during which transgenic tRNAs are present in transfected
cells, we performed successive transfections, with a second
transfection on the 3rd day after the ﬁrst one. MELAS
cybrid cell line used has defective steady-state level of the
mtDNA-encoded COX2 subunit and decreased cyto-
chrome c oxidase (COX) enzymatic activity, which is in
agreement with previously published data (40). We
analyzed steady-state level of COX2 protein during 6
days after transfection by immunoblotting of total cell
protein extracts (Figure 3B). For several tRNA versions,
reproducible increase of COX2 was observed with the
most pronounced effect detected after transfection with
tRK2CAA, where COX2 level was increased approxi-
mately three times as compared to non-transfected
cybrid cells with its maximum being at the fourth day
(1 day after the second transfection). tRK1UAA version
also caused a two-fold increase of COX2 on the ﬁfth day
(2 days after second transfection), while tRK1CAA
induced only a slight increase (1.5 times) 1 day after ﬁrst
transfection. The increase of COX2 level was however
temporary in all assays, which is in agreement with the
transient presence of recombinant RNAs in transfected
cells.
The presence of recombinant tRNA versions in mito-
chondria of transfected cells was checked by Northern
hybridisation (Figure 3C, left panel). All three
Figure 2. Analysis of in vivo import of synthetic recombinant tRNAs in mitochondria of MELAS cybrid cells. (A) Northern hybridization of total
and mitochondrial RNA isolated from MELAS cybrid cells transfected with T7-transcripts. Speciﬁc [32P]-oligonucleotide probes to tRK1, tRK2 and
tRK3 were used to check for mitochondrial import, mt-tRNA-Leu probe—to control the absence of degradation of mitochondrial tRNAs and
cy-tRNA-Lys probe to control the absence of its contamination by cytosolic tRNAs (the probes are indicated at the right of the panels). Minor
bands visible with tRK1 probe in tRK2-transfectants and with cy-tRNA-Lys probe in tRK1 and tRK2 ones represent the unwashed traces of
previous hybridizations of the same membrane and are unspeciﬁc (they do not migrate as the cognate tRNAs and therefore do not alter any
interpretation of the speciﬁc signals). TH and MH are total and mitochondrial RNAs from non-transfected MELAS cells, TY stands for total yeast
RNA used as the control of hybridization speciﬁcity. T1 and T3 are the transcripts of yeast tRK1 and tRK3 without mutations used to estimate the
import efﬁciency of recombinant tRNAs (B) Relative amount of imported recombinant tRNAs calculated as a ratio of hybridization signals for
recombinant tRNAs in mitochondrial RNA fraction to that of mt-tRNALeu in the same preparation. The import efﬁciencies presented on the graph
represent relative values in comparison to these of tRK1 or tRK3 taken as 1.0 in each series. The presented error bars are issued from several
independent experiments, as indicated above the diagrams.
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recombinant versions were present in mitochondria which
did not contain any detectable cytosolic contamination.
tRK1 versions were analysed along with T7 transcripts
of tRK1, tRK2 and mt-tRNALeu, which permitted quan-
tiﬁcation of the import (Figure 3C, right panel). The
amount of all three versions was signiﬁcantly lower than
that of the reference host mt-tRNALeu, which can explain
the limited effect of their expression on COX2 level, so far
this recovery effect was observed in all the cases in a
reproducible manner.
Generation of MELAS cybrid cells stably expressing
leucine recombinant tRNA genes
In an attempt to stabilize the curative effect of mitochon-
drial import of recombinant tRNAs, we used the lentiviral
transfection system. tRNA genes were cloned in the vector
pLKO.1 under the control of an external U6 RpoIII
promoter. Before infection, pLKO.1-tRK constructs were
ﬁrst veriﬁed in the transient transfection system, in which
expression of tRK1UAA/CAA and tRK2UAA/CAA was
observed. For stable lentiviral transfection, MELAS
cybrid cells were analyzed 72 h or 96 h after infection for
transgene expression, and tRK1CAA was found to be the
only one stably and efﬁciently expressed (Figure 4A).
Other constructs, giving no sufﬁcient levels of expression
(although the presence of the transgene was conﬁrmed by
PCR) were not analyzed further. The MELAS-pLKO.1-
tRK1CAA cell line was therefore analyzed in depth.
Furthermore, this very version proved to be the most pro-
spective one, taking into account its best aminoacylation
properties (Table 1) and import capacity comparable with
other versions.
Figure 3. Effect of transient expression of recombinant tRNAs on COXII level in MELAS cybrid cells. (A) Northern hybridization analysis of total
RNAs isolated from pBK-CMV-tRK transfected MELAS cybrid cells. Cells were transfected twice, second transfection was performed on the third
day after the ﬁrst one, and RNAs were isolated 1–6 days after the ﬁrst transfection. Speciﬁc [32P]-oligonucleotide probes are indicated on the left of
the autoradiographs (tRK1, tRK2 or cy-tRNALys—for the control cytoplasmic tRNALys used as the quantiﬁcation reference). (B) Western analysis
of protein extracts from the transfected cells with anti-COX2 antibodies. Anti-tubulin antibodies were used as the quantiﬁcation reference. Two
different MW zones of the same blot were analyzed for COX2 and tubulin. The steady-state levels of COX2 before and after transfection, normalized
to tubulin, are shown as diagrams for each tRNA-version in the lower panel of the ﬁgure. Values are presented relative to COX2 level in 143B
parental cells, taken as 1. Error bars correspond to the results of 3–5 independent assays. (C) Northern hybridization of total (T) and mitochondrial
(M) RNA isolated from MELAS cybrid cells 24 h after transient transfection with recombinant tRNAs. Hybridisation probes are indicated at the
left. Transfected RNAs (tRK1UAA; tRK1CAA, tRK2CAA) and quantitative controls (2 ng of T7-transcritpts of tRK1, tr1, tRK2, tr2 and
mt-tRNALeu, trL) are indicated at the top. The diagram at the right is a result of at least two independent experiments, as indicated.
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By Northern hybridization analysis of puriﬁed mito-
chondrial RNA, we have shown that fraction of
tRK1CAA was imported into mitochondria of MELAS-
pLKO.1-tRK1CAA cells (Figure 4A), which conﬁrmed
our results obtained with T7-transcripts. RNA acid gel
analysis demonstrated that at least a part of recombinant
tRK1CAA in MELAS cells was aminoacylated
(Figure 4B). Comparing the distance between aminoacy-
lated and not aminoacylated forms of tRK1CAA and of
other cellular tRNAs, we concluded, that the upper band
corresponded to tRK1CAA aminoacylated with leucine.
The middle band could correspond to tRK1CAA
aminoacylated with lysine, so far, taking into account its
low lysinylation level in vitro (Table 1) and the fact that
the same band is detectable in both native and deacylated
preparations, we suggest rather a non-speciﬁc signal.
Furthermore, a possible unspeciﬁc aminoacylation is
most likely done by cytoplasmic LysRS rather than by
its mitochondrial counterpart taken into account that in
mitochondria the amount of tRK1CAA is lower and mito-
chondrial LeuRS is present as a competitor. Therefore we
hope that the minor portion of tRK1CAA possibly
charged with lysine, if any, would have no considerable
effects either on mitochondrial translation, or on cytosolic
protein synthesis. Since leucine identity elements for human
mitochondrial LeuRS we introduced in tRK1CAA were
distinct from those for cytosolic LeuRS (44), and taking
into account the possibility to leucinylate the recombinant
tRNA in vitro, we conclude that tRK1CAA was amino-
acylated with the leucine by mitochondrial LeuRS after its
mitochondrial import. The portion of leucinylated
tRK1CAA is modest probably because of non-optimal
aminoacylation efﬁciency of recombinant tRNAs in vivo,
but also because of naturally low amounts of tRNAs
imported into mitochondria.
The above conclusions were veriﬁed by measuring the
extent of tRK1CAA leucinylation in mitochondrial RNA
preparations (Figure 4C). We compared the stable
Figure 4. Import and aminoacylation of tRK1CAA stably expressed in MELAS cells. (A) Northern hybridization of total (t) and mitochondrial
RNA (mt) from MEL-pLKO.1-T1CAA (MEL-T1C), MEL-pLKO.1 (MEL-pLKO) human cells and yeast with tRK1 and cy-tRNALys-speciﬁc [32P]-
labelled oligonucleotide probes. (B) Acid gel and northern analysis of total RNAs isolated from MEL-T1C, MEL-pLKO, 143B human cells and
yeast with tRK1, mt-tRNALeu, cy-tRNALys and cy-RNAMet-speciﬁc [32P]-labelled oligonucleotide probes (aa, aminoacylated RNA; da, RNA par-
tially deacylated in basic conditions before loading). (C) Acid gel and northern analysis of mitochondrial RNA isolated from parental 143B and
MEL-T1C cells. Aminoacylated and deacylted forms of mt-tRNALeu, mt-tRNAThr and tRK1CAA are indicated. The diagram at the right shows the
quantiﬁcation of aminoacylation levels for all these tRNAs (tRK1CAA was not analysed in the parental line since this RNA is absent therein).
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tRK1CAA expressor with the MELAS cybrid line and
observed, as expected, a very low aminoacyaltion level
for the host mt-tRNALeu affected by the mutation
(10–20%). At the same time the overall level of tRNA
aminoacylation (as judged by the reference mt-tRNAThr)
was high (>70%). The recombinant tRK1CAA was found
partially aminoacylated (50–60%), which is signiﬁcantly
more pronounced than in the total RNA. This result is
in agreement with the speculations above, and is likely to
be explained by the efﬁcient aminoacylation by the LeuRS
in the mitochondria, while the major portion of deacylated
tRK1CAA resides in the cytosol of the transfectant.
Therefore, one can consider that if the level of import
may be low (if comparable with the transient expression
experiment), the aminoacylation by the mitochondrial
enzyme was rather efﬁcient and therefore one could
expect to detect the curative effect.
Improvement of mitochondrial functions in
MELAS-pLKO.1-tRK1CAA cells
In agreement with previous reports (11,21), the original
MELAS cybrid cells showed strongly decreased mitochon-
drial protein synthesis, with large polypeptides ND2,
COX1, COX2 and COX3 being particularly affected, but
the qualitative pattern of mitochondrial translation prod-
ucts was unchanged. In MELAS-pLKO.1-tRK1CAA cells
amounts of mitochondrial translation products were
found to be increased to 30–50% in a generalized manner,
compared to control cells transfected with an empty vector
(MELAS-pLKO.1) (Figure 5). Further western analysis of
mitochondrial DNA-encoded respiratory subunits reve-
aled a reproducible increase of COX2 (+22%) and ND1
(+10%) proteins in MELAS cells stably expressing
tRK1CAA transgene (Figure 6).
Oxygen consumption levels in MELAS-pLKO.1-
tRK1CAA and MELAS cells transfected with the empty
plasmid were then compared (Figure 7A and B). The ref-
erence MELAS-pLKO.1 cells demonstrated strongly decr-
eased respiration with the ratio of uncoupled to coupled
respiration (respiratory control) approximately two times
lower than for 143B cells, which was in agreement with
previously reported data (19). In MELAS-pLKO.1-
tRK1CAA cells the rates of coupled and uncoupled oxy-
gen consumption were increased about two times in com-
parison with the respective rates in MELAS-pLKO.1 cells,
while respiration control was also improved.
To decipher this positive effect on cellular respiration,
substrate-dependent oxygen consumption on digitonin
permeabilized cells was analyzed. MELAS and 143B
cells revealed similar succinate-supported respiration
rates through complex II entirely encoded by nuclear
DNA (Figure 7C). This succinate-supported respiration
was not affected by tRK1CAA expression, as expected.
In contrast, there was a substantial decrease in respir-
ation rate through complex IV in MELAS-pLKO.1
cells comparing to 143B cells (Figure 7D). Importantly,
this ascorbate-supported respiration was strongly incre-
ased in the MELAS cells with tRK1CAA, which con-
ﬁrmed previously observed rise of COX2 steady-state
level and general improvement of mitochondrial
translation.
Since the high heteroplasmy level in MELAS-pLKO.1-
tRK1CAA was unchanged upon transfection (90%),
one can conclude that the observed functional im-
provement of mitochondrial functions was due to ex-
pression and mitochondrial import of the recombinant
tRNA.
DISCUSSION
The results of this study clearly demonstrate that one can
alter aminoacylation identity of a tRNA preserving its
ability to be imported in vivo into human mitochondria
and to participate in the organellar translation. Indeed, we
Figure 5. Mitochondrial translation in MELAS-pLKO-tRK1CAA
cybrid cells. (A) Pulse-chase analysis of mitochondrial translation.
Radioautograph of [35S]-labelled mitochondrial translation products
separated by SDS–PAGE is presented. The lines used are indicated at
the top: 143B, MEL-pLKO and MEL-T1C. The bands corresponding
to individual translation products are indicated according to standard
pattern (56). Equal amounts of proteins were loaded in each case,
which was controlled by Western analysis of porin in the same
samples performed in parallel (below the main panel). (B) The
diagram shows the levels of individual translation products in each
cell line relative to those in 143B cells (taken as 1).
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Figure 7. Oxygen consumption in MELAS-pLKO-tRK1CAA cybrid cells. (A) The rates of coupled and uncoupled oxygen consumption (the mean
values±SD, n=3) in 143B, MEL-pLKO and MEL-T1C cell lines in nmol O2/10
6 cell*min. (B) Box and whisker plots (57) represent the ratios of
uncoupled to coupled respiration rates in 143B, MEL-pLKO and MEL-T1C cell lines. The overall data range is represented as a vertical line, while
boxes represent the interquartile range containing central 50% data. (C) The rates of the respiration on succinate in permeabilized 143B, MEL-pLKO
and MEL-T1C cells. (D) The rates of the respiration on ascorbate in permeabilized 143B, MEL-pLKO and MEL-T1C cells.
Figure 6. Steady-state level of mitochondrial proteins in MELAS-pLKO-tRK1CAA cybrid cells. (A) Western analysis of protein extracts from 143B,
MEL-pLKO and MEL-T1C cell lines with antibodies against mitochondrial proteins COX2, ND1 and tubulin. (B) COX2 and ND1 steady-state
levels in each cell line, normalized to tubulin and relative to the steady-state level of the corresponding protein in parental 143B cells (taken as 1).
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show that nuclear expression and subsequent mitochon-
drial import of speciﬁcally designed tRNAs of yeast origin
with artiﬁcially changed identity (cytoplasmic lysine to
mitochondrial leucine) partially rescues various negative
effects of the mutation m.3243A>G in the mitochondrial
tRNALeu gene underlying the MELAS syndrome in cul-
tured human cells. This rescue was observed at the levels
of mitochondrial translation, steady state of mitochon-
drial DNA-encoded subunits of the respiratory chain
and cellular respiration.
The increase of COX2 steady-state level that we observed
in MELAS cells in transient transfection system varied in
strength and duration depending on tRNA version ex-
pressed (Figure 3). This could indicate on possible differ-
ences in behaviour and action of different recombinant
tRNAs in the cell. Thus, lower import efﬁciency of
tRK1CAA comparing to tRK1UAA (Figure 2) can par-
tially explain its moderate effect on COX2 level. On the
other hand, the less efﬁcient import substrate tRK2CAA
lead to the best improvement of COX2 level, probably
taking advantage of its CAA anti-codon, which did
not need post-transcriptional modiﬁcation to decode
leucine UUG codons. This experimental fact is in frame
of a suggestion that the MELAS mutation might affect
essentially decoding UUG, but not UUA. On the other
hand, it is to be outlined that the improvement of mito-
chondrial function depended not only on the efﬁciency of
a particular tRNA to participate in mitochondrial trans-
lation, but also on the time it was present in cell. For
example, the effect of tRK1CAA on COX2 steady-state
level was more pronounced once it has been expressed in
cybrid cells in a stable manner. The importance of the
effect depends on a multitude of linked or non-linked
factors inﬂuencing each step of the experiment: efﬁciency
of transfection, efﬁciency of expression of the tRNA gene,
efﬁciency of import, mitochondrial activity state that may
vary signiﬁcantly even in continuously cultivated
line, modiﬁcation and aminoacylation of the transgenic
tRNAs, the stability of the given transgenic tRNA in
the cell and in the mitochondria, misaminoacylation of
the tRNA, which can give negative effects on mitochon-
drial or cytoplasmic translation, etc. On the other hand,
if the efﬁciency of different versions varies, all of
them provided a detectable and reproducible curative
effect, thus validating the strategy, whose efﬁciency cer-
tainly needs to be improved to make it applicable in
therapy.
Meanwhile, MELAS-pLKO.1-tRK1CAA cells clearly
demonstrated a signiﬁcant rescue of mitochondrial func-
tions at all levels analyzed (Figures 5–7). Thus, synthesis
of certain polypeptides reached or even exceeded (for
ND2, CytB and ATP6) its level in 143B wild type cells,
while synthesis of others was improved up to 30% (for
COX1)—50% (for COX2/3) of its wild-type level,
indicating that tRK1CAA participated in mitochondrial
translation. However, no clear correlation between
number of leucine codons (neither UUG, nor UUR) and
translation level of particular mitochondrial proteins was
observed in MELAS cybrid cell before or after transfec-
tion, which is corroborated by previously reported data
(11,21). The partial nature of the effect could be explained
by insufﬁcient level of expression of the recombinant
tRNA gene(s), defective post-transcriptional modiﬁca-
tions of recombinant tRNAs, ineffective export of
tRNAs from nucleus and targeting into mitochondria
or, ﬁnally, low efﬁciency of re-aminoacylation inside the
organelle. Furthermore, one could also imagine that the
growth conditions used (high glucose and pyruvate) do
not favour the switch from glycolysis to oxidative phos-
phorylation in transfected cybrid cells energy production.
In any case, the observed increase of mitochondrial trans-
lation level and subsequent augmentation of COX2 and
ND1 steady states was sufﬁcient to improve the rate of
oxygen consumption in MELAS-pLKO.1-tRK1CAA cells
about 2-fold. Such an increase may prove to be sufﬁcient
for further therapeutic application. The question that
might emerge, is the validity of the strategy described
here for various cell/tissue types. The efﬁciency of the
approach relies to the RNA import mechanism, which is
far to be understood in details. Indeed, our studies of the
human RNA import (both natural, for 5S rRNA, and
artiﬁcial, for tRNA derivatives) indicate on the import-
ance of the membrane charge and ATP hydrolysis for
import (31,54). It was reported that isolated and
discharged mitochondria from cybrid cells bearing a
pathogenic mutation fail to incorporate tRNAs (33). So
far, these data are in contradiction with our previously
published report of the in vivo import of tRNALys deriva-
tives which, in spite of the lower energized state of
mitochondria in MERRF cybrids can import tRNAs
enough to complement mitochondrial deﬁciency (39). So,
we believe that, since no mtDNA mutation described led
to a complete discharging of the mitochondrial membrane
potential, one could expect the possibility to target RNAs
into mitochondria. As a conﬁrmation of our former study,
the results obtained in the current work show that in the
strongly affected cybrid cell line tRNA import may be
achieved and the phenotypic effect is measurable, if even
the cells were affected by another mutation (MELAS
versus MERRF) and the phenotypic alteration caused
by the mutation were different. On the other hand, it is
evident that the efﬁciency of the approach will not only
depend on the efﬁciency of import per se, but also on the
amount of the ‘therapeutic’ RNA in a given type of cell,
which will depend on the delivery procedure, as well as on
the functionality of the tRNA itself, in terms of
aminoacylation and decoding properties.
In conclusion, the recombinant leucine tRNAs vali-
dated in the present work could be tested in modelling
therapeutic approaches to a number of other disorders
caused by dysfunction of mt-tRNALeu(UUR). As an im-
portant issue of the study, it clearly appears that the mito-
chondrial translation system in human cells possesses a
signiﬁcant extent of ﬂexibility, accepting not only
cytosolic-type tRNAs, but also tRNAs of yeast origin,
which are evolutionary very distinct from the human
ones. This makes us believe that the strategy developed
in this study can be applied to all tRNA mutations
which are not affecting the overall expression of
mtDNA, however for each case the importable and func-
tionally active molecule must be designed. Construction of
these new importable versions may be helped by a
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comprehensive view of the mechanisms governing the se-
lectivity of tRNA import, taking into account the
identiﬁed import determinants (42,51,55) and the possibil-
ity of their structural rearrangements (52). The new obser-
vations, together with previously published data (38,39),
strongly support the approach of allotopic expression of
mitochondrially targeted RNAs as a powerful tool for dif-
ferent kinds of disorders caused by mutations in mito-
chondrial tRNA-coding genes.
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